AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ACRES Commercial Realty Corp.
Video analysis: ACR
All videosNo video analysis for this stock yet. Request one from our team.
News: ACR
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.
CORRECTING and REPLACING Amid Declining Book Value, ACRES Commercial Realty Struggles to Sell REO Property Due to Labor Dispute with Philadelphia Hospitality Union UNITE HERE Local 274
PHILADELPHIA--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the first paragraph. The updated release reads: AMID DECLINING BOOK VALUE, ACRES COMMERCIAL REALTY STRUGGLES TO SELL REO PROPERTY DUE TO LABOR DISPUTE WITH PHILADELPHIA HOSPITALITY UNION UNITE HERE LOCAL 274 UNITE HERE Local 274 has learned that ACRES Commercial Realty (NYSE:ACR) recently told investors that ‘not having a contract' was ‘holding up efforts' to sell its Phil.
Amid Declining Book Value, ACRES Commercial Realty Struggles to Sell REO Property Due to Labor Dispute with Philadelphia Hospitality Union UNITE HERE Local 274
PHILADELPHIA--(BUSINESS WIRE)--UNITE HERE Local 274 has learned that ACRES Commercial Realty (NYSE:ACR), after declaring impasse and walking away from contract negotiations with workers at its Philadelphia hotel property in March, recently told investors that “not having a contract” was “holding up” efforts to sell the hotel. ACR released its Q2 2026 earnings report on July 29, 2026, posting a GAAP net loss allocable to common shares of $12.5 million. In an earnings call the following day, ACR.
ACRES COMMERCIAL REALTY CORP. ANNOUNCES COMPLETION OF MERGER, INTERNALIZATION AND PRIVATE NOTES OFFERING
Completion of Merger and Internalization UNIONDALE, N.Y., Aug. 6, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "ACR" or "Company") announced today that it has completed its previously disclosed acquisition of ACRES Capital Corp. ("ACC") in an all-stock transaction (the "Merger") and transitioned from an externally-managed REIT to an internally-managed REIT (the "Internalization").
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC), as well as endometrial, cervical, and esophago-gastric junction cancers WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that ACR-2316 has advanced into the randomized dose expansion portion of its ongoing Phase 1/2 study.
ACRES Commercial Realty: Why We Are Staying Neutral On ACRES Series C Preferred
ACRES Commercial Realty Corp. posted a disappointing Q2 2026, with book value dropping 10% to $26.76/share. Management internalization drove significant one-time costs, with $4.9M in equity compensation and $5.1M in merger expenses impacting net income. The capital structure is unusually preferred-heavy, with $224M in preferred equity versus $189M in common, raising concerns for preferred holders.
ACRES Commercial Realty Corp. (ACR) Q2 2026 Earnings Call Transcript
ACRES Commercial Realty Corp. (ACR) Q2 2026 Earnings Call Transcript
ACRES Commercial (ACR) Reports Q2 Loss, Misses Revenue Estimates
ACRES Commercial (ACR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.04 per share a year ago.
Similar companies
-
Seven Hills Realty Trust
SEVN
·
NASDAQ
Compare
-
Granite Point Mortgage Trust Inc.
GPMT
·
New York Stock Exchange
Compare
-
Franklin Street Properties Corp.
FSP
·
New York Stock Exchange Arca
Compare
-
Strawberry Fields REIT, Inc.
STRW
·
New York Stock Exchange Arca
Compare
-
Cherry Hill Mortgage Investment Corporation
CHMI
·
New York Stock Exchange
Compare
-
Orion Properties Inc.
ONL
·
New York Stock Exchange
Compare